Indirect Comparison Of Pembrolizumab To Vemurafenib And Dabrafenib Monotherapy For First-Line Treatment Of Advanced Melanoma In Braf Mutation Positive Ipilimumab Naïve Patients
May 1, 2016, 00:00
10.1016/j.jval.2016.03.1650
https://www.valueinhealthjournal.com/article/S1098-3015(16)01718-6/fulltext
Title :
Indirect Comparison Of Pembrolizumab To Vemurafenib And Dabrafenib Monotherapy For First-Line Treatment Of Advanced Melanoma In Braf Mutation Positive Ipilimumab Naïve Patients
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01718-6&doi=10.1016/j.jval.2016.03.1650
First page :
A138
Section Title :
Cancer - Clinical Outcomes Studies
Open access? :
No
Section Order :
237